In a strategic move to strengthen its oncology pipeline, Astellas Pharma has entered into an exclusive ex-China license agreement with Evopoint Biosciences for the development and commercialisation of XNW27011, a clinical-stage antibody-drug conjugate (ADC) targeting CLDN18.2. Currently in Phase I/II trials, XNW27011 has shown promising monotherapy activity in gastrointestinal cancers. The deal includes a US$130 M upfront payment, up to US$1.41 B in potential milestone payments, and tiered royalties, enabling Astellas to expand its precision oncology portfolio while accelerating global development of this novel ADC.